Aims: Drug-eluting stents (DES) were first used on-label - in simple patients with low clinical risk and easily accessible lesions. Currently, DES are increasingly used off-label - in com
Hanim Sen1, MD; Ming Kai Lam1, MD; Kenneth Tandjung1, MD, PhD; Mounir W.Z. Basalus1, MD, PhD; Frits H.A.F. de Man1, MD, PhD; J. Hans W. Louwerenburg1, MD; Martin G. Stoel1, MD, PhD; Gert K. van Houwelingen1, MD; Marije M. Löwik1, PhD; Gerard C.M. Linssen2, MD, PhD; Salah A.M. Saïd2, MD, PhD; Mark B. Nienhuis3, MD, PhD; Patrick M.J. Verhorst1, MD, PhD; Job van der Palen1. Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands; 2. Department of Cardiology, Ziekenhuisgroep Twente, Almelo and Hengelo, The Netherlands; 3. Department of Cardiology, Streekziekenhuis Koningin Beatrix
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
complex patientsclinical researchoff-labelpercutaneous coronary interventionrandomised controlled trialtwente trial
Read next articleComparison of acute gain and late lumen loss after PCI with bioresorbable vascular scaffolds versus everolimus-eluting stents: an exploratory observational study prior to a randomised trial